Roche’s pharmaceutical production facility in Boulder, Colorado.
BOULDER, US: The Roche Group and International Chemical Investors Group (ICIG) agreed for ICIG to acquire Roche Colorado Corporation, which includes Roche’s pharmaceutical production facility in Boulder, Colorado. As per the agreement, ICIG will acquire the Roche affiliate company in Boulder with its technical development and small molecule manufacturing capabilities. Roche Colorado currently has a workforce of approximately 265 employees.
ICIG intends to operate the Boulder site, renamed “Corden Pharma Colorado Inc,” as part of its pharmaceutical business. Corden Pharma is the pharmaceutical arm of ICIG investments. Also Corden Pharma Colorado will supply Roche with a number of active pharmaceutical ingredients (API) that the Boulder site produces.
“Selling the Boulder site to ICIG will secure a reliable supplier to meet Roche’s demand for commercial scale peptides and other medicinal compounds,” said Dr Georg Wiebecke, Head of Chemical Manufacturing, Roche.
Roche’s Boulder facility produces therapeutic peptide compounds, having pioneered large scale synthetic manufacturing technologies. The Boulder site is also capable of producing complex small molecules and highly potent compounds.
“With this purchase, we form a commanding presence in contract peptide manufacturing industry,” said Dr Wolfgang Niedermaier, President, Corden Pharma. “This will help us to expand the market for Boulder site’s unique technical capabilities, attracting additional API production opportunities that will build on its existing portfolio of Roche products.”
© WOC News